Literature DB >> 21225291

Reversal of rocuronium-induced neuromuscular block by sugammadex is independent of renal perfusion in anesthetized cats.

Lonneke M Staals1, Hans D de Boer, Jan van Egmond, Frank Hope, Francien van de Pol, Anton H Bom, Jacques J Driessen, Leo H D J Booij.   

Abstract

PURPOSE: Sugammadex is a selective relaxant binding agent designed to encapsulate the aminosteroidal neuromuscular blocking agent rocuronium, thereby reversing its effect. Both sugammadex and the sugammadex-rocuronium complex are eliminated by the kidneys. This study investigated the effect of sugammadex on recovery of rocuronium-induced neuromuscular block in cats with clamped renal pedicles, as a model for acute renal failure.
METHODS: Twelve male cats were divided into two groups and anesthetized with medetomidine, ketamine, and alpha-chloralose. The cats were intubated and ventilated with a mixture of oxygen and air. Neuromuscular monitoring was performed by single twitch monitoring. Rocuronium 0.5 mg/kg i.v. was administered. After spontaneous recovery from neuromuscular block, both renal pedicles were ligated. A second dose of rocuronium 0.5 mg/kg i.v. was given. One minute after disappearance of the twitches, in Group 1 placebo (0.9% saline) and in Group 2 sugammadex 5.0 mg/kg i.v. was administered. Onset time, duration of neuromuscular block, and time to recovery to 25, 50, 75, and 90% were determined.
RESULTS: After renal pedicle ligation, sugammadex reversed rocuronium-induced neuromuscular block significantly faster than spontaneous recovery. Mean time (SEM) to 90% recovery of the twitch response was 4.7 (0.25) min (Group 2) versus 31.1 (5.0) min (Group 1) (p < 0.0001). No signs of recurrence of neuromuscular block were observed for 90 min after complete twitch restoration. Sugammadex caused no significant cardiovascular effects.
CONCLUSION: Sugammadex rapidly and effectively reversed rocuronium-induced neuromuscular block in anesthetized cats, even when both renal pedicles were ligated and renal elimination of the drugs was no longer possible.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21225291     DOI: 10.1007/s00540-010-1090-3

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  18 in total

1.  Urinary, biliary and faecal excretion of rocuronium in humans.

Authors:  J H Proost; L I Eriksson; R K Mirakhur; G Roest; J M Wierda
Journal:  Br J Anaesth       Date:  2000-11       Impact factor: 9.166

2.  A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host.

Authors:  Anton Bom; Mark Bradley; Ken Cameron; John K Clark; Jan Van Egmond; Helen Feilden; Elizabeth J MacLean; Alan W Muir; Ronald Palin; David C Rees; Ming-Qiang Zhang
Journal:  Angew Chem Int Ed Engl       Date:  2002-01-18       Impact factor: 15.336

3.  Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision.

Authors:  T Fuchs-Buder; C Claudius; L T Skovgaard; L I Eriksson; R K Mirakhur; J Viby-Mogensen
Journal:  Acta Anaesthesiol Scand       Date:  2007-08       Impact factor: 2.105

4.  Preclinical pharmacology of sugammadex.

Authors:  Anton Bom; Frank Hope; Samantha Rutherford; Karen Thomson
Journal:  J Crit Care       Date:  2009-03       Impact factor: 3.425

5.  Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study.

Authors:  L M Staals; M M J Snoeck; J J Driessen; H W van Hamersvelt; E A Flockton; M W van den Heuvel; J M Hunter
Journal:  Br J Anaesth       Date:  2010-01       Impact factor: 9.166

6.  The neuromuscular blocking effects and pharmacokinetics of ORG 9426 and ORG 9616 in the cat.

Authors:  K Khuenl-Brady; K P Castagnoli; P C Canfell; J E Caldwell; S Agoston; R D Miller
Journal:  Anesthesiology       Date:  1990-04       Impact factor: 7.892

7.  First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide.

Authors:  Francois Gijsenbergh; Steven Ramael; Natalie Houwing; Thijs van Iersel
Journal:  Anesthesiology       Date:  2005-10       Impact factor: 7.892

8.  Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure.

Authors:  R A Cooper; V R Maddineni; R K Mirakhur; J M Wierda; M Brady; K T Fitzpatrick
Journal:  Br J Anaesth       Date:  1993-08       Impact factor: 9.166

9.  Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function.

Authors:  L M Staals; M M J Snoeck; J J Driessen; E A Flockton; M Heeringa; J M Hunter
Journal:  Br J Anaesth       Date:  2008-07-23       Impact factor: 9.166

Review 10.  Reversal of neuromuscular block.

Authors:  A Srivastava; J M Hunter
Journal:  Br J Anaesth       Date:  2009-05-24       Impact factor: 9.166

View more
  5 in total

1.  Effects of sugammadex on immunoreactivity of calcineurin in rat testes cells after neuromuscular block: a pilot study.

Authors:  Yıldıray Kalkan; Levent Tümkaya; Habib Bostan; Yakup Tomak; Adnan Yılmaz
Journal:  J Mol Histol       Date:  2011-12-29       Impact factor: 2.611

2.  Population pharmacokinetic-pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-induced neuromuscular blockade.

Authors:  Huub J Kleijn; Daniel P Zollinger; Michiel W van den Heuvel; Thomas Kerbusch
Journal:  Br J Clin Pharmacol       Date:  2011-09       Impact factor: 4.335

3.  Impact on grafted kidney function of rocuronium-sugammadex vs cisatracurium-neostigmine strategy for neuromuscular block management. An Italian single-center, 2014-2017 retrospective cohort case-control study.

Authors:  M Carron; G Andreatta; E Pesenti; A De Cassai; P Feltracco; F Linassi; M Sergi; C Di Bella; M Di Bello; F Neri; C Silvestre; L Furian; P Navalesi
Journal:  Perioper Med (Lond)       Date:  2022-01-13

Review 4.  Sugammadex as a reversal agent for neuromuscular block: an evidence-based review.

Authors:  Stefan Josef Schaller; Heidrun Fink
Journal:  Core Evid       Date:  2013-09-25

Review 5.  Advantages and pitfalls of clinical application of sugammadex.

Authors:  Hyung Young Lee; Ki Tae Jung
Journal:  Anesth Pain Med (Seoul)       Date:  2020-07-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.